|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07C 51/43 | (2006.01) |
| C07C 51/43 | (2013.01) | ||
| C07C 59/70 | (2006.01) | ||
| A61K 38/28 | (2013.01) | ||
| A61K 38/28 | (2006.01) | ||
| A61K 31/5575 | (2013.01) | ||
| A61K 31/5575 | (2006.01) | ||
| A61P 3/10 | (2018.01) | ||
| A61P 3/10 | (2006.01) | ||
| A61P 9/08 | (2018.01) | ||
| A61P 9/08 | (2006.01) |
| (11) | Number of the document | 3853200 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19773695.2 |
| Date of filing the European patent application | 2019-09-11 | |
| (97) | Date of publication of the European application | 2021-07-28 |
| (45) | Date of publication and mention of the grant of the patent | 2024-01-24 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2019/050632 |
| Date | 2019-09-11 |
| (87) | Number | WO 2020/060823 |
| Date | 2020-03-26 |
| (30) | Number | Date | Country code |
| 201862732799 P | 2018-09-18 | US |
| (72) |
REMICK, David Michael , US
|
| (73) |
Eli Lilly and Company ,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
| (54) | ERBUMINE SALT OF TREPROSTINIL |
| ERBUMINE SALT OF TREPROSTINIL |